Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:QUCY NASDAQ:SNGX NASDAQ:VYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.47+1.6%$5.12$7.96▼$24.15$22.54M0.6315,685 shs22,095 shsQUCYMainz Biomed$1.46-2.3%$1.66$0.30▼$4.93$21.84M2.224.98 million shs1.91 million shsSNGXSoligenix$0.39+2.6%$0.62$0.28▼$6.23$5.65M1.8416.33 million shs972,131 shsVYNEVYNE Therapeutics$0.65+0.1%$0.66$0.28▼$1.96$21.68M2108,280 shs162,544 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+1.59%+2.29%-9.15%-26.90%+89.41%QUCYMainz Biomed-2.35%-23.42%-56.31%+210.10%+145,499,900.00%SNGXSoligenix+2.62%-2.74%+0.23%-67.69%-70.60%VYNEVYNE Therapeutics+0.09%+3.09%-3.10%+5.36%-38.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.47+1.6%$5.12$7.96▼$24.15$22.54M0.6315,685 shs22,095 shsQUCYMainz Biomed$1.46-2.3%$1.66$0.30▼$4.93$21.84M2.224.98 million shs1.91 million shsSNGXSoligenix$0.39+2.6%$0.62$0.28▼$6.23$5.65M1.8416.33 million shs972,131 shsVYNEVYNE Therapeutics$0.65+0.1%$0.66$0.28▼$1.96$21.68M2108,280 shs162,544 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+1.59%+2.29%-9.15%-26.90%+89.41%QUCYMainz Biomed-2.35%-23.42%-56.31%+210.10%+145,499,900.00%SNGXSoligenix+2.62%-2.74%+0.23%-67.69%-70.60%VYNEVYNE Therapeutics+0.09%+3.09%-3.10%+5.36%-38.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AQUCYMainz Biomed 1.50ReduceN/AN/ASNGXSoligenix 2.00Hold$6.001,434.53% UpsideVYNEVYNE Therapeutics 1.75ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest SNGX, ALVR, QUCY, and VYNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/4/2026VYNEVYNE Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026SNGXSoligenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AQUCYMainz Biomed$540K39.50N/AN/A$0.07 per share20.79SNGXSoligenix$120K48.29N/AN/A$0.52 per share0.75VYNEVYNE Therapeutics$570K38.07N/AN/A$0.83 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/AQUCYMainz Biomed-$16.21M-$47.60N/AN/AN/AN/AN/AN/AN/ASNGXSoligenix-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)VYNEVYNE Therapeutics-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%8/13/2026 (Estimated)Latest SNGX, ALVR, QUCY, and VYNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026VYNEVYNE Therapeutics-$0.18-$0.08+$0.10-$0.08$0.20 million$0.09 million5/8/2026Q1 2026SNGXSoligenix-$0.30-$0.28+$0.02-$0.28N/AN/A3/31/2026Q4 2025QUCYMainz BiomedN/A-$0.0250N/A-$0.0250N/A$0.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AQUCYMainz BiomedN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78QUCYMainz BiomedN/A2.112.11SNGXSoligenixN/A1.811.81VYNEVYNE TherapeuticsN/A20.8620.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%QUCYMainz BiomedN/ASNGXSoligenix3.60%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%QUCYMainz Biomed3.10%SNGXSoligenix3.05%VYNEVYNE Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionNo DataQUCYMainz Biomed3014.66 million14.21 millionN/ASNGXSoligenix2014.82 million14.37 millionNot OptionableVYNEVYNE Therapeutics3033.35 million32.34 millionNot OptionableSNGX, ALVR, QUCY, and VYNE HeadlinesRecent News About These CompaniesVYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04May 15, 2026 | msn.comShareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersDecember 18, 2025 | prnewswire.com3 penny stocks to watch now, 12/18/25December 18, 2025 | msn.comVYNE to merge with Yarrow in $200 million dealDecember 18, 2025 | thepharmaletter.comTRoundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow BioscienceDecember 17, 2025 | pharmexec.comP$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)December 17, 2025 | prnewswire.comVYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to ShareholdersDecember 17, 2025 | businesswire.comVYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks TranscriptDecember 17, 2025 | seekingalpha.comVyne Therapeutics stock soars after merger with Yarrow BioscienceDecember 17, 2025 | za.investing.comVyne Therapeutics, Yarrow Bioscience to MergeDecember 17, 2025 | marketwatch.comVyne Therapeutics shares surge on merger deal with Yarrow BioscienceDecember 17, 2025 | msn.comVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementDecember 17, 2025 | globenewswire.comVYNE Therapeutics Approves Director Elections and ProposalsDecember 12, 2025 | tipranks.comVYNE Therapeutics reports Q3 EPS (17c) vs (29c) last yearNovember 6, 2025 | msn.comVYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesNovember 6, 2025 | zacks.comVYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateNovember 6, 2025 | globenewswire.comIncyte scraps BET inhibitor against backdrop of safety concerns for the drug classOctober 28, 2025 | fiercebiotech.comFVYNE Therapeutics (VYNE) Price Target Decreased by 22.00% to 3.32October 1, 2025 | msn.comVYNE Therapeutics Faces Nasdaq Non-Compliance NoticeSeptember 12, 2025 | msn.comVYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 19, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNGX, ALVR, QUCY, and VYNE Company DescriptionsAlloVir NASDAQ:ALVR$4.47 +0.07 (+1.59%) As of 06/23/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Mainz Biomed NASDAQ:QUCY$1.46 -0.04 (-2.35%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$1.46 +0.00 (+0.34%) As of 06:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Soligenix NASDAQ:SNGX$0.39 +0.01 (+2.62%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.39 0.00 (-0.51%) As of 06:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.VYNE Therapeutics NASDAQ:VYNE$0.65 +0.00 (+0.09%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.60%) As of 06:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
